Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Safinamide studied in phase III trial for Parkinson's

Sep. 15, 2004

Orphan drug designation for ProCord

Sep. 15, 2004

Antinociceptive effects of N-acetylaspartylglutamate peptidase inhibitors in vivo

Sep. 15, 2004

Pharmagene describes furan-based prostanoid EP4 antagonist for migraine therapy

Sep. 15, 2004

New alpha2C-adrenoceptor antagonists identified at Juvantia

Sep. 15, 2004

Rivastigmine reported to slow cognitive decline in AD regardless of disease severity

Sep. 14, 2004

TheraQuest Biosciences discovers analgesic synergy with narcotics

Sep. 14, 2004

Positive phase IIb results for harkoseride in epilepsy

Sep. 14, 2004

New alpha2, alpha3 and/or alpha5-selective GABA-A receptor ligands claimed by Merck

Sep. 14, 2004

Pfizer claims new 5-HT7 receptor modulators for depression, anxiety, etc.

Sep. 14, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...